InflaRx’s (IFRX) Buy Rating Reiterated at Guggenheim

Guggenheim restated their buy rating on shares of InflaRx (NASDAQ:IFRX) in a research note published on Tuesday,Benzinga reports. Guggenheim currently has a $14.00 price objective on the stock.

Several other equities research analysts also recently issued reports on IFRX. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research note on Friday, March 27th. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of InflaRx in a research note on Tuesday, December 30th. Finally, Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a research note on Wednesday, December 31st. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $6.17.

InflaRx Trading Down 2.5%

Shares of InflaRx stock opened at $1.56 on Tuesday. The company’s fifty day simple moving average is $1.01 and its 200-day simple moving average is $1.10. The company has a market cap of $112.77 million, a price-to-earnings ratio of -2.05 and a beta of 1.49. InflaRx has a 1 year low of $0.71 and a 1 year high of $1.94.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Friday, March 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). The company had revenue of ($0.04) million during the quarter, compared to analyst estimates of $0.03 million. As a group, research analysts forecast that InflaRx will post -0.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InflaRx

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE bought a new position in shares of InflaRx in the third quarter valued at about $3,316,000. Suvretta Capital Management LLC raised its holdings in shares of InflaRx by 22.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after buying an additional 1,450,000 shares during the last quarter. 683 Capital Management LLC raised its holdings in shares of InflaRx by 47.3% in the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock valued at $3,348,000 after buying an additional 1,065,000 shares during the last quarter. Woodline Partners LP bought a new position in shares of InflaRx in the first quarter valued at about $766,000. Finally, Adage Capital Partners GP L.L.C. bought a new position in shares of InflaRx in the second quarter valued at about $262,000. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.